Bothell, WA-based Marina Biotech will put its Smarticles liposomal delivery technology to work for ProNAi Therapeutics in a discovery pact revolving around DNAi-based therapeutics. Marina Biotech stands to gain up to $14 million for each gene target in total upfront, clinical and commercialization milestone payments, as well as royalties. ProNAi will have the option to select any number of additional gene targets. Release